Qualified Health and the University of Texas System use Claude to identify patients who need life-saving care

Get started

Get started

Industry:

Healthcare

Company size:

Large

Product:

AI Platform

Location:

North America

4–6 million patients per year

in Texas qualify for evidence-based interventions but never get identified

1 million+ patient population

at The University of Texas Medical Branch now being screened by protocols built on Claude to identify candidates for intervention

Qualified Health is a healthcare-native AI platform that identifies patients who qualify for life-saving treatments and improved evidence-based management but who would otherwise go undetected. The University of Texas System is one of the largest public university systems in the United States, with health institutions serving patients across Texas.

With Claude, Qualified Health and the UT System:

  • Screen a 2 million patient population to identify candidates for life-saving interventions
  • Route eligible patients directly into clinicians’ workflows with supporting documentation
  • Complete chart reviews in minutes that previously required extensive manual abstraction
  • Identify patients who benefit from medication optimization, therapeutic intervention, or further discussion
  • Plan to expand from cardiology to primary care, vascular, GI, rheumatology, and neurology by end of 2026

The problem

In Texas, almost every county experiences some critical physician shortage. Healthcare providers know that catching diseases earlier leads to better outcomes, but the information needed to identify at-risk patients is buried in fragmented clinical data that no human could reasonably review at scale.

“People both want and deserve a level of access to healthcare that our workforce can’t realistically deliver without AI augmentation,” said Dr. Peter McCaffrey, Chief Digital and AI Officer at the University of Texas Medical Branch (UTMB).

Healthcare systems spent years digitizing their records, but digitization didn’t make the data usable. “The problem we face is literally one of search, retrieval, and comprehension,” McCaffrey said. “It’s 90% of what we do. It’s where so much of our workforce gets burned out and it’s where most care gaps accumulate. The size and scope of that data are only growing, the breadth of our responsibility to patients is only growing, but our workforce is not keeping pace.”

Organizations ended up with vast amounts of unstructured clinical notes, imaging reports, and test results scattered across disconnected systems. A patient may receive a new diagnosis of heart failure and may be started on therapy, but those medications and dosages may not align with the latest guidelines. Meanwhile, a Cardiology team–even at the same hospital–may be aware of the latest guidelines, but they would not be aware of whether newly diagnosed patients are receiving guideline-directed care even though doing so improves mortality. In Texas, an estimated 4–6 million patients qualify for evidence-based interventions each year and never get identified—resulting in preventable deaths, avoidable complications, and growing strain on the healthcare system.

Claude powers population-scale patient identification

Qualified Health built an AI platform with Claude Sonnet 4.5 to help health systems identify patients who qualify for proven, evidence-based interventions at population scale. Claude was selected following a structured evaluation of multiple models, based on its performance in accurately extracting clinical information, minimizing hallucinations, and producing outputs that are fully traceable to source data, capabilities required for safe use in clinical settings.

The platform integrates fragmented clinical data, such as notes, laboratory results, imaging, and procedural records, and applies precise, guideline-based clinical criteria to determine patient eligibility across a broad set of cardiology practices. 

Patients who meet those criteria are surfaced directly into clinicians’ existing workflows for review, with supporting documentation generated to trace each finding back to source data. This approach shortens the path from identification to treatment while preserving clinician oversight, enabling health systems to deliver evidence-based care more consistently and at a scale that was previously infeasible.

From reactive care to proactive intervention

Justin Norden, MD, a physician and computer scientist, founded Qualified Health to help health systems deploy AI safely and at scale across clinical and administrative operations, enabling clinicians to find and treat patients who would otherwise fall through the cracks. His previous company focused on algorithm safety and trust in high-risk environments before being acquired for autonomous vehicle applications. That background shaped Qualified Health’s approach: building the infrastructure needed to monitor, validate, and govern AI performance in high-risk healthcare settings.

“If we caught patients earlier and intervened, that would be better for everyone. That’s very well known,” said Norden. “What is not yet well known is that today, we have the potential to do that.”

The partnership with the UT System began when Dr. McCaffrey was expanding his AI leadership role at UTMB. The institution needed a partner who could help them move fast and demonstrate real value, not just run interesting experiments. “We’re not so much interested in, oh, you did something that looks cool on a poster,” Dr. McCaffrey explained. “At this stage, we need true examples where AI is deployed in practice and it brings value to care because that is our mandate.”

For cardiologists at UTMB’s Sealy Heart and Vascular Institute, the workflow is straightforward. They log into Qualified Health’s platform and see a census of patients who have been pre-screened by AI and who have opportunities for more optimized management in areas like heart-failure and valvular disease. The system then brings forward relevant medical and historical context balanced with evidence-based appropriateness criteria to highlight those who might otherwise go unnoticed but who would benefit from improved management. The Claude-powered AI platform surfaces relevant details from each patient’s chart, extracting and synthesizing information that would be impossible to manually compile across a patient population.

“I could spend hours looking through charts and find things to worry about,” Norden said. “But you can’t do that on 10,000 patients.” The system doesn’t replace clinical judgment, he added. It amplifies it, enabling clinicians to apply their expertise at a scope that was previously impossible.

Choosing Claude for clinical accuracy

Qualified Health continuously evaluates multiple large language models through a rigorous internal benchmarking process that combines automated testing with structured review by practicing physicians. Models are assessed on their ability to accurately extract structured clinical information from complex source data, minimize failure modes such as hallucinations, and provide traceable citations back to underlying records.

“Our focus is on precision and reliability,” Norden said. “We need models that can consistently identify the right clinical signals, avoid introducing errors, and make every output fully referenceable to the source data. In our evaluations for this work, Claude demonstrated the strongest performance across those dimensions.”

“Safety is non-negotiable in healthcare,” Norden added. “Anthropic has been a clear leader in building models with strong safety foundations, and that was an important factor in our decision-making.”

The validation process reflects Qualified Health’s roots in algorithmic safety and clinical rigor. Each deployment follows a staged approach that includes retrospective back-testing on historical data, automated evaluations, structured physician review, and controlled rollouts prior to broader use with partners.

“There are no fully automated clinical decisions being made,” Norden emphasized. “Every output is reviewed by clinicians, with direct validation against source data. Human oversight is built into the system by design.”

The outcome

In the first month of deployment, the platform revealed that as many as a third of patients with heart failure have opportunities for improved optimization in guideline directed medical therapy. In the initial wave of review, this translated into dozens of patients with opportunities for evidence-based improvement in medication management which cardiologists could then validate and notify care teams. “This is a great example of AI actively augmenting the clinical workforce”, McCaffrey said. “It’s well known that many patients with heart failure can benefit from improved pharmacologic management but examining this adherence and medication practice across a population just isn’t feasible; we don’t have the clinician bandwidth for that.”

The approach extends beyond cardiology. “We started in cardiology, but this isn’t just a cardiology tool,” McCaffrey noted. “It’s the same problem everywhere—there’s a patient in GI with early cirrhosis, there’s someone in vascular with an aneurysm that’s never been flagged. The information is there. We just haven’t had a scalable way to surface it. The need isn’t for AI to make medical decisions; instead, the need is to bring buried issues to the foreground so that clinicians can make medical decisions.”

Cardiology was a deliberate starting point as a specialty with well-established diagnostic criteria, clear clinical guidelines, and availability of proven interventions with life-saving potential.

Building on UTMB’s success, the initiative is now expanding system-wide. By the end of 2026, new deployments will help health systems across Texas identify patients eligible for evidence-based treatments in primary care, vascular, gastrointestinal, rheumatology, and neurology specialties. Dr. McCaffrey chairs AI work across all UT System health institutions, and the system views itself as responsible for all Texans across its exceptional geographic, medical, and socioeconomic diversity.

Dr. McCaffrey added: “Being able to scale that intelligence, that clinical reasoning, to everyone, everywhere is a really inherent social good.” 

‍Worth accessing:

Qualified Healthhttps://www.qualifiedhealthai.com

Advancing Claude in healthcare and the life sciences

Transform healthcare from insight to action

Read more

Read more

Claude for Healthcare

Claude helps healthcare organizations move faster without sacrificing accuracy, safety, or compliance. Less administrative work, more time with the people you serve.

Read more

Read more

“Safety is non-negotiable in healthcare. Anthropic has been a clear leader in building models with strong safety foundations.”

Justin Norden, MD

Co-Founder, Qualified Health

Posted in Uncategorized | Tagged , , , , | Leave a comment

Hassan Sajwani: “This is an engineer from Elon Musk’s xAI …

Posted in Uncategorized | Leave a comment

The Economist: Who had the most contact with Jeffrey Epstein in the final decade of his life?

Posted in Uncategorized | Leave a comment

In 2012, Jeffrey Epstein spent more than $200,000 to get his last lover, Karina Shuliak, into Columbia University’s dental school.

Chay Bowes

@BowesChay

In 2012, Jeffrey Epstein spent more than $200,000 to get his last lover, Karina Shuliak, into Columbia University’s dental school. She initially failed the selection process, but Epstein told the university he would donate between $5 million and $10 million, the dean of the dental school received $100,000 for his research project, and another $50,000 went into the faculty’s “budget” As a result, Shuliak was able to transfer from a Belarusian university despite violating deadlines, and an individual study program was prepared for her. The key link in this “arrangement” was Epstein’s personal dentist, Thomas Mangani. After the scandal, Mangani left the Columbia University admissions committee, and Professor Letty Moss-Salanté was stripped of her administrative duties. Former dean Ira Lamster, who left the university in 2017, said he knew about Epstein’s crimes but believed he had “paid back society for his sins”.

Posted in Uncategorized | Leave a comment

OCCRP: Much of the frenzied Jeffrey Epstein commentary over the past two weeks has focused on individual examples of moral depravity.But there’s a wider, more systemic story here.

February 13, 2026

Greetings from Amsterdam,

Much of the frenzied Jeffrey Epstein commentary over the past two weeks has focused on individual examples of moral depravity. But there’s a wider, more systemic story here. As Seva Gunitsky, a political scientist at the University of Toronto, has argued, the documents “suggest a reframing of Epstein’s case from one man’s crimes to transnational geopolitics.”Viewed through this lens, Epstein’s incredible collection of powerful and influential contacts, from tech billionaires to FSB officers, perfectly exemplifies a new transnational elite — one that has “built fortunes by moving money across jurisdictions, leveraging kompromat, and treating governments as service providers instead of sovereigns.”Epstein’s role shows how this class of operators has been enabled by willing Western partners. Our recent reporting offers three snapshots of how that works.


Start with Senegal: the documents trace a years-long relationship between Epstein and Karim Wade, son of former President Abdoulaye Wade and once one of the country’s most powerful ministers. After Wade’s corruption conviction, his team sought help lobbying in Washington — and turned to Epstein for guidance.Then Venezuela: emails show Epstein buying bonds tied to PDVSA, the state oil company, on the advice of Francisco D’Agostino — a Chávez-era insider now wanted by Venezuelan authorities on money-laundering and criminal-association charges.

Epstein’s social capital also paid dividends back in New York. Emails indicate he worked to secure employment at the International Peace Institute — a respected policy institution tied to the United Nations — for a Russian romantic partner. He may even have subsidized her pay. The commonality in these vignettes is not sex, and it’s not even ideology. It’s the indispensable role of powerful intermediaries who can turn money into legitimacy, access, and impunity — not to mention a powerful reminder of how much of this brokerage usually happens in the dark.The analysis above is a free preview of our upcoming OCCRP PRO membership, a new offering tailored to professionals who rely on our investigations for work in finance, law, compliance, risk management, policy, and related fields. Interested to learn more? Let us know and tell us what you need! Your feedback will directly shape the services we build.OCCRP Exclusive
Posted in Uncategorized | Tagged , , , , | Leave a comment

CNN: Epstein paid for novel genetic testing in apparent effort to explore extending life, new emails show

Epstein paid for novel genetic testing in apparent effort to explore extending life, new emails show

By

Sarah Owermohle

Updated Feb 6, 2026

Late financier and convicted sex offender Jeffrey Epstein is seen in this image from the U.S. Justice Department’s file of Epstein, released by the House Oversight Committee Democrats Washington, D.C., on December 18, 2025.

Late financier and convicted sex offender Jeffrey Epstein is seen in this image from the U.S. Justice Department’s file of Epstein, released by the House Oversight Committee Democrats Washington, D.C., on December 18, 2025. House Oversight Committee Democrats/Reuters

Convicted sex offender Jeffrey Epstein paid for genetic testing in an apparent bid to harness his own genetic material for regenerative medicine – which is aimed at repairing the body by developing new tissues and organs as the old ones wear out – according to newly released emails in the Epstein files.

Several years after Epstein was convicted of soliciting prostitution, including of a minor, in 2008, he paid for novel tests from a doctor at one of America’s preeminent hospitals and explored creating stem cells central to immunity and healing.

The researcher, Joseph Thakuria, was at the time a senior doctor at Massachusetts General Hospital (MGH) in Boston and affiliated with a large-scale genomic studies project at Harvard Medical School.

In a statement to CNN, Thakuria said Epstein was also enrolled in the Harvard Personal Genome Project, a massive public global database of genetic information from volunteers for scientists and researchers to learn more about traits and genes.

Thakuria has not been publicly linked to Epstein before and is not accused of any wrongdoing.

A Harvard representative said MGH is an affiliate of Harvard, but Thakuria was not directly employed by Harvard or the Wyss Institute, which oversees the Personal Genome Project. MGH has no record of approving Thakuria for studies described in the Epstein emails.

Thakuria left the hospital in 2022, an MGH spokesperson said.

Among the documents in the Epstein files released by the Justice Department is a proposal that Thakuria sent Epstein in February 2014, appealing to him to fund a private project that would sequence his patients’ genomes to learn about genetic drivers for their diseases. In the proposal, he also raises options for genetic investigations specifically for Epstein.

A few months later, in June, Thakuria sent Epstein an extensive invoice for a range of projects that included an initial $2,000 investment for sequencing part of Epstein’s genome. The invoice included an estimated cost for “personalized longevity studies” that proposed using gene editing. The invoice indicated that Epstein gave a saliva sample.

The initial investment included $1,000 to sequence a portion of his genome known as the exome, and $1,000 to sequence fibroblasts, which are cells found in connective tissue such as skin and muscles, and that have been used in a relatively new field of research aimed at reversing aging.

Epstein’s staff sent a $2,000 check the same day.

Billionaire Jeffrey Epstein in Cambridge, Massachusetts in 2004.

Billionaire Jeffrey Epstein in Cambridge, Massachusetts in 2004. Rick Friedman/Corbis/Getty Images

“Mr. Epstein was enrolled in the Personal Genome Project, which would study his genetic predisposition to various health conditions. At one point, a $2,000 check was provided to cover DNA sequencing,” Thakuria said in the statement.

“I was a physician-researcher and he [Epstein] was a research subject,” he added. “We also had early discussions about his potentially funding research, but that never materialized.”

“I feel terrible about what his victims went through, and I regret at that time not knowing more about his background and the extent of his crimes,” Thakuria said.

Part of the proposal involved editing Epstein’s stem cells “to introduce mutations in culture believed to increase longevity,” using the then-novel gene editing technology CRISPR, Thakuria wrote.

“I’m only offering this to Jeffrey. Because of all the labor involved, there’s simply not enough bandwidth to offer this to more than a handful of people right now,” he added.

The invoice gave a range of options for future research such as creating new stem cells starting at $10,000, and broader longevity studies that included other patients, and indicated that it could cost “$11,400 for his [Epstein’s] whole genome ($21,000 if he wanted to include both of his parents; not sure if this is even feasible)” to be sequenced.

The full breadth of the projects proposed as described in the invoice would have cost $193,400.

CNN did not find a record of Epstein paying for those services, but emails continued between Thakuria, Epstein and his assistants until at least 2015. In these, Epstein’s assistants sought to follow up on Thakuria’s initial work. At one point, Epstein became annoyed with Thakuria for delays and threatened to report him to his bosses if results did not come quickly.

EFTA00348068-1.jpg

Department of Justice

Epstein died by suicide in 2019 while awaiting trial on federal sex-trafficking charges.

The disgraced financier had long been interested in gene editing. Through his now-defunct foundation, Epstein donated to the World Transhumanist Association, now called Humanity+, as the New York Times first reported in 2019. Humanity+ advocates for “technology and evidence-based science to expand human capabilities” and reverse aging.

Epstein also reportedly had discussions with scientists where he mulled using his own genes to seed a new human race.

The most recently released emails shed new light on Epstein’s relationships with top scientists in the field of genomics research and raise questions about how some may have sought funding from him.

In his statement to CNN, Thakuria said he was introduced to Epstein by George Church, a high-profile Harvard genomics researcher, as a potential research subject for the Personal Genome Project.

Church, who has pioneered gene editing with the then-novel CRISPR technology — used to cut, add and modify specific genetic sequences — has previously been associated with Epstein, who emailed with him frequently and donated funds to his research. Church apologized in 2019 for his continued association with Epstein, calling it “nerd tunnel vision” in an interview with STAT.

Church, who has not been accused of any wrongdoing related to Epstein, did not return a request for comment from CNN. The spokesperson for Harvard referred CNN to Church’s remarks from 2019 in response to questions about him.

Some of what Thakuria described in his invoice was opaque. The largest single item in the invoice was $160,000 for research he called “The Venus Project.”

EFTA02698643-2.jpg

Department of Justice

“Jeffrey and [I] briefly discussed a genomic research studying [sic] I’m dubbing the Venus project (he’ll know what this),” Thakuria wrote in the June 2014 invoice. “I can do this for him but doing this work would be greatly aided by having some good bioinformatic infrastructure.”

“[Epstein] mentioned 200 participants being in this project — I can deliver on this ‘Venus’ research,” he added.

In his statement to CNN, Thakuria said the project was “an idea of Mr. Epstein that was very preliminary and never went anywhere.”

“He was interested in the genetics of facial features. There was no funding, and no research.”

Posted in Uncategorized | Tagged , , , , | Leave a comment

Sky News: Extremists jailed for plotting ‘deadliest’ terror attack on UK Jewish community

Posted in Uncategorized | Leave a comment

Neuroscience News: Hippocampus Predicts Rewards by Reorganizing Memories

The image shows a drawing of a hippocampus.

The image of the hippocampus in the public domain.

Hippocampus Predicts Rewards by Reorganizing Memories

ElectrophysiologyFeaturedNeuroscience

·January 29, 2026

Summary: A new preclinical study reveals that the hippocampus does more than just store memories; it actively reorganizes them to predict future rewards. By tracking brain activity over several weeks, researchers discovered that hippocampal neurons shift their activity to fire before a reward is reached, essentially building a predictive model of the world. These findings offer a new framework for understanding why learning and decision-making are often the first functions to decline in Alzheimer’s disease.

Source: McGill University

Key Facts:

  • Predictive Mapping: The hippocampus updates its “internal model” of the world daily, shifting neural activity from the moment of reward to the moments leading up to it.
  • Advanced Imaging: Researchers used calcium imaging (making neurons glow) to track specific cells over weeks, capturing slow learning processes invisible to traditional electrodes.
  • Beyond Pavlov: While simple reward learning is linked to primitive brain circuits, this study shows the hippocampus uses complex memory and context for sophisticated anticipation.
  • Alzheimer’s Insight: The breakdown of this predictive signaling may explain why Alzheimer’s patients struggle with decision-making and learning from new experiences.

A preclinical study published in Nature has found evidence that the hippocampus, the brain region that stores memory, also reorganizes memories to anticipate future outcomes.

The findings, from researchers at the Brandon Lab at McGill University and their collaborators at Harvard University, reveal a learning process that had not been directly observed before.

“The hippocampus is often described as the brain’s internal model of the world,” said senior author Mark Brandon, Associate Professor in McGill’s Department of Psychiatry and Researcher at the Douglas Research Centre. “What we are seeing is that this model is not static; it is updated day by day as the brain learns from prediction errors. As outcomes become expected, hippocampal neurons start to respond earlier as they learn what will happen next.”

A new view of learning in action

The hippocampus builds maps of physical space and past experiences that help us make sense of the world. Scientists have known these maps change over time as brain activity patterns shift, a phenomenon that is currently assumed to be random.

The new findings demonstrate the changes are not random, but structured. Researchers obtained these findings by tracking brain activity in mice as the mice learned a task with a predictable reward.

“What we found was surprising,” said Brandon. “Neural activity that initially peaked at the reward gradually shifted to earlier moments, eventually appearing before mice reached the reward.”

Rather than relying on traditional electrodes, which can only track neurons for short periods, the researchers used new imaging techniques that cause active neurons to glow. The Brandon Lab is among the first in Canada to use this technology, enabling the team to follow cells over several weeks and track slow changes that traditional methods often miss.

Insights into learning and Alzheimer’s disease

Simpler forms of reward learning have long been associated with more primitive brain circuits, as famously demonstrated by Ivan Pavlov’s experiments, which showed that animals can associate a cue, such as a bell, with food. The new findings suggest the hippocampus supports a more sophisticated version of this process, using memory and context to anticipate outcomes.

Alzheimer’s disease patients often struggle not only to remember the past but also to learn from experience and make decisions. By showing that the healthy hippocampus helps turn memories into predictions, the study offers a new framework for understanding why learning and decision-making are affected early in Alzheimer’s disease and opens the door to research into how this predictive signal may fail and be restored.

Editorial Notes

  • This article was edited by a Neuroscience News editor.
  • Journal paper reviewed in full.
  • Additional context added by our staff.

About this Hippocampus Research

  • Source: McGill University
  • Contact: Keila DePape
  • Image: The image is in the public domain

Original Research:
Predictive Coding of Reward in the Hippocampus” by Mohammad Yaghoubi and Mark Brandon et al., was published in Nature. This research was supported by funding from Fonds de recherche du Québec – Santé and the Canadian Institutes of Health Research.
DOI: 10.1038/s41586-025-09958-0 

About the Brandon Lab

The Brandon Lab was founded in 2015 at the Douglas Research Centre at McGill University by Professor Mark Brandon. The lab investigates the core mechanisms of memory, including how memories are encoded, stored, and retrieved in the brain. It also studies how memory breaks down in Alzheimer’s disease, with the goal of identifying strategies to protect and restore memory.

Posted in Uncategorized | Tagged , , , , | Leave a comment

GZERO: Ian Bremmer … Munich Security Conference: Can Europe Stand Alone?

Posted in Uncategorized | Leave a comment

GZERO: Are we in an era of “wrecking ball politics” : Global Stage

Posted in Uncategorized | Leave a comment